WuXi PharmaTech's CEO has teamed up with a major investor in an attempt to take the CRO private, pitching a buyout that would give the Chinese company's shareholders a 16.2% premium.
With Mylan's second bid for Perrigo, it actually hit below the first bid the Irish drugmaker rejected, Perrigo contended. But now, Mylan is back with a third offer to set things straight.
Orphan meds have been like catnip for drugmakers for several years, driving many an M&A deal. Now, Swedish Orphan Biovitrum might be next in line, at a price of more than $3.5 billion.
On Friday, Mylan all but rejected Teva's takeover bid with its own sweetened bid for Ireland's Perrigo. But now, it's made the snub official, delivering a resounding "no" to its generics rival.
A few years after teaming up with Versant Ventures to get Stanford spinout Quanticel Pharmaceuticals off the ground, Celgene is buying the cancer-focused biotech for up to $485 million.
Sweden's Sobi, a close partner of Biogen, is in the crosshairs of a buyout bid. But the biotech isn't saying yet just who's doing the bidding.
Just a couple hours after Mylan sweetened its original bid for Ireland's Perrigo to $31 billion-plus, Perrigo nixed the new offer. Why? The way the target sees it, it isn't quite so sweet.
Mylan sent a message to Teva that it wasn't interested in becoming bait even before the Israeli drugmaker made its $40 billion bid earlier this week. Now, it's repeating that message loud and clear--and it's doing so with a sweetened offer for Irish target Perrigo.
Biopharma production specialist Sartorius Stedim Biotech has acquired BioOutsource, a U.K. CRO focused on the growing demand for knockoffs of top-selling biologics.
While pharma's been riding its deal wave, Gilead's been off on its own, coasting on new revenue from blockbuster hep C launches Sovaldi and Harvoni. But one analysts thinks the time is ripe for it to get in on the M&A action--and he's tabbed Vertex as a prime target.